Results 21 to 30 of about 5,796 (217)

Linking pharmacy dispensing data to other administrative health datasets to measure the compliance and effectiveness of RSV immunoprophylaxis

International Journal of Population Data Science, 2018
Introduction Respiratory Syncytial Virus (RSV) causes considerable morbidity in children. RSV vaccines are in development, but the only current preventive measure is immunoprophylaxis with monoclonal antibody, palivizumab.
Hannah Moore, Tobias Strunk, Tasnim Abdalla, Tom Snelling, Peter Richmond, Anthony Keil, Nicholas de Klerk   +6 more
doaj   +1 more source

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

BMC Pediatrics, 2020
Background The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV).
Ruomei Xu, Parveen Fathima, Tobias Strunk, Nicholas de Klerk, Thomas L. Snelling, Peter C. Richmond, Anthony D. Keil, Hannah C. Moore   +7 more
doaj   +1 more source

Partial Degradation of Recombinant Antibody Functional Activity During Infant Gastrointestinal Digestion: Implications for Oral Antibody Supplementation

Frontiers in Nutrition, 2020
Oral administration of engineered immunoglobulins has the potential to prevent enteric pathogen-induced diarrhea in infants. To prevent infection, these antibodies need to survive functionally intact in the proteolytic environment of the gastrointestinal
Baidya Nath P. Sah, Jiraporn Lueangsakulthai, Bum Jin Kim, Benjamin R. Hauser, Yeonhee Woo, Amy Olyaei, Molly Aloia, Ann O'Connor, Brian Scottoline, Manoj K. Pastey, David C. Dallas   +10 more
doaj   +1 more source

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children

Drugs in Context, 2015
Background: The peak season of respiratory syncytial virus (RSV) infections in warmer climates may extend beyond the typical five-month RSV season of temperate regions. Additional monthly doses of palivizumab may be necessary in warmer regions to protect
Saleh al-Alaiyan, Paul Pollack, Gerard F Notario   +2 more
doaj   +1 more source

Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study

Italian Journal of Pediatrics, 2023
Background In children with congenital heart disease (CHD) respiratory syncytial virus (RSV) infection may have a severe course, with increased risk of morbidity and mortality, requiring hospital admission and intensive care. The aim of the present study
Chiara Ratti, Anna della Greca, Deborah Bertoncelli, Monica Rubini, Bertrand Tchana   +4 more
doaj   +1 more source

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010

Emerging Infectious Diseases, 2012
To assess molecular evolution of the respiratory syncytial virus (RSV) fusion gene, we analyzed RSV-positive specimens from 123 children in Canada who did or did not receive RSV immunoprophylaxis (palivizumab) during 2006–2010.
Jesse Papenburg, Julie Carbonneau, Marie-Ève Hamelin, Sandra Isabel, Xavier Bouhy, Najwa Ohoumanne, Pierre Déry, Bosco A. Paes, Jacques Corbeil, Michel G. Bergeron, Gaston De Serres, Guy Boivin   +11 more
doaj   +1 more source

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia

Journal of Allergy and Clinical Immunology: Global, 2023
Background: Infants with respiratory-syncytial virus bronchiolitis hospitalization are more likely to develop wheezing and subsequent asthma. Reportedly, palivizumab prophylaxis effectively prevents respiratory-syncytial virus hospitalization in high ...
Li-Ching Fang, MD, Jen-Yu Wang, MD, Hsin-Hui Yu, MD, PhD, Li-Chieh Wang, MD, PhD, Bor-Luen Chiang, MD, PhD   +4 more
doaj   +1 more source

Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia

Journal of Infection in Developing Countries, 2021
Introduction: Respiratory syncytial virus (RSV) is one of the most important childhood infections. Objective: To evaluate the effectiveness and safety of palivizumab immunoprophylaxis in preterm infants at a high risk of severe respiratory syncytial ...
Juan Gabriel Piñeros, Jose De la Hoz-Valle, Clara Galvis, Astrid Celis, Oscar Ovalle, Carmen Cecilia Sandoval, Jaime Orrego, Saby Vides, Iader Rojas, Hernando Bustamante, Carlos Gallón, Jaime Alberto Mesa   +11 more
doaj   +1 more source

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

Italian Journal of Pediatrics, 2009
Introduction The aim of this study was to assess the cost-utility of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm infants.
Ravasio Roberto, Chirico Gaetano, Sbarigia Urbano   +2 more
doaj   +1 more source

Subcutaneous palivizumab (Synagis®) administration in an infant with congenital type 2B von Willebrand disease

Journal of Pediatric and Neonatal Individualized Medicine, 2015
Intramuscular injections are contra-indicated in infants with either acquired or congenital bleeding disorders. In such patients, it is unlicensed practice to administer vaccines by subcutaneous route.
Karel Allegaert, Maissa Rayyan, Veerle Cossey, Chris Van Geet   +3 more
doaj   +1 more source